Under the “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” Executive Order issued in May 2025, the Trump administration promoted a framework for MFN-participating manufacturers to sell prescription drugs direct-to-patients (DTP).
As of December 11, 2025, a variety of manufacturers have reached agreements or stated their intent to offer discounted prices for some of their medications through TrumpRx. However, these discounts have so far been limited to products that were already offered at reduced prices and primarily benefited patients who were un- or under-insured, limiting the impact on manufacturers.
CRA’s Matthew Majewski dives into the implications for payers, PBMs, and manufacturers as the DTP marketplace emerges. The TrumpRx.gov portal is scheduled to launch in January 2026 and will serve as a central platform for patients to access DTP options from participating manufacturers.
Read more about TrumpRX enabling direct-to-patient care here.
